Health System

A panel discussion at the 2022 American Academy of Dermatology Annual Meeting addressed the association between food and skin manifestations, as well as dietary triggers and recommendations in the management of a myriad of dermatologic conditions.

Late-breaking findings at the 2022 American Academy of Dermatology Annual Meeting showed ruxolitinib cream was associated with clinically significant improvement in facial and total body repigmentation vs vehicle in the treatment of adolescent and adult patients with nonsegmental vitiligo over 52 weeks.

Jonathan Silverberg, MD, PhD, MPH, discusses key differences regarding epidemiology, genetic risk factors, and clinical manifestations of pediatric and adult-onset atopic dermatitis, as well as recommended therapeutic approaches for adult patients.

Melissa Johnson, MD, program director of Lung Cancer Research at Sarah Cannon, explains factors inhibiting uptake of next-generation sequencing testing among patients with lung cancer.

The FDA accepts an application for a drug to treat amyotriphic lateral sclerosis (ALS) for review; vaccines have been found to reduce people’s risk for developing long COVID-19; COTA announces Miruna Sasu, PhD, as its new president and CEO.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital, spoke on considerations for dermatologists in seeking payer coverage of novel, expensive therapies for atopic dermatitis.

Lower risk of discontinuation was found with ustekinumab vs the biologics adalimumab, secukinumab, and ixekizumab, in the treatment of patients with moderate to severe psoriasis.

Coverage of COVID-19 tests and treatment bills halted for uninsured; Moderna low-dose vaccine in children under 6 years of age shows promise in early clinical trial findings; Pfizer recalls blood pressure medications due to potential carcinogen.

Patients with chronic rhinosinusitis (CRS) with nasal polyps exhibited significant improvement in olfactory function when treated with a combination of oral and nasal steroids vs nasal steroids alone.

At the 2022 Community Oncology Conference, Elizabeth Spurlock, MA, PHR, director, Human Resources Business Partner, Texas Oncology, discussed the prevalence of burnout among physicians, staff, and administrators, and several strategies to reduce risk and support the health care workforce.

The special enrollment period for Affordable Care Act (ACA) coverage has opened to low-income Americans; the FDA approves the first drug for a rare genetic epilepsy disorder; the National Institutes of Health to launch biomarker testing program for pediatric tumors.

Taiwanese patients with psoriasis were found to be at greater risk of developing gout; nonsteroidal anti-inflammatory drug use was shown to decrease such risk.

Emerging research on therapeutics and practical approaches to managing a myriad of dermatological conditions, as well as a growing focus on diversity, equity, and inclusion will be explored at the 2022 American Academy of Dermatology (AAD) Annual Meeting, which will take place March 25-29, in Boston, Massachusetts.

Lalan Wilfong, MD, vice president of Payer Relations & Practice Transformation at The US Oncology Network, speaks on how use of health economics and outcomes research has benefitted patient care in the community oncology setting and where it can be further leveraged in the pursuit of value-based care.

Jim Schwartz, RPh, corporate pharmacy manager, Texas Oncology, discussed pharmacy challenges regarding equitable care and distribution of specialty drugs in the community oncology setting.

Addressing avoidable emergency department (ED) utilization takes interventions in partnership with providers.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

Ben Jones, vice president, Government Relations & Public Policy, The US Oncology Network, addresses potential reform at the federal and state level that could accelerate the pursuit of value-based care in the community oncology setting.

Michael Diaz, MD, president and managing physician, Florida Cancer Specialists & Research Institute, speaks on takeaways from his discussions on site of care and pharmacy benefit managers (PBMs) at the 2022 Community Oncology Conference.

Medicare advantage beneficiaries who received care from providers in 2-sided risk payment models had lower rates of acute care use, according to new study findings.

The study called for increased education, productive health care professional dialogue, and shared decision-making in the management of patients with psoriasis and psoriatic arthritis.

Along with common symptoms of itch and pain, patients with atopic dermatitis experience significant work productivity and attention issues that affect overall quality of life, said Robert Sidbury, MD, MPH, chief, Division of Dermatology, Seattle Children's Hospital.

FDA issued a complete response letter (CRL) to AstraZeneca seeking additional clinical data for benralizumab, sold as Fasenra, in the treatment of patients with inadequately controlled chronic rhinosinusitis with nasal polyps.

Idaho legislature passed Texas-inspired abortion law banning the procedure after 6 weeks of pregnancy; patients who were bedridden with severe cases of COVID-19 had increased risks of anxiety and depression more than a year later; number of deaths by suicide in Japanese women rose for second straight year.